Since the previous announcement on October 30, 2025, “Overseas Expansion into Japan,” responsible for “Chinese-language Distribution of Japan Information” within “Drug R&D Expert”, has published Issue 25 (Series B – Part 10: Exclusive Sales Rights for Japanese Ethical Drugs published on November  7, 2025) and Issue 26 (Series A – Part 9: Japan’s Efforts to Promote DCT (Part 2) published on December 5, 2025).

■Issue 25 (Series B – Part 10): Exclusive Sales Rights for Japanese Ethical Drugs published on November 7, 2025 (in Chinese)

PharmaDJ Website

https://www.pharmadj.com/ssr/article/1982446196058296322

PharmaDJ WeChat

https://mp.weixin.qq.com/s/VjAbdpM6WfQDwkllgu9u8g

■Issue No. 26 (Series A – Part 9): Japan’s Efforts to Promote DCT (Part 2) published on December 5, 2025 (in Chinese)

PharmaDJ Website

https://www.pharmadj.com/ssr/article/1996791390383673346

Please note that issues 27 through 32 are currently suspended due to circumstances.

We sincerely apologize to our readers for any concern and/or inconvenience this may cause.

When we are able to resume publication, we will announce it on this website, etc.  We kindly ask our readers for your patience and understanding during this period.

Tetsuomi Takano, Editor-in-Chief, Drug R&D Expert
医药研发达人主编　高野哲臣